このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

The Effect of Acupuncture on Brain-Derived Exosomal Load, Cognitive Function, and Sleep Disturbances in Patients With Fibromyalgia.

2026年11月16日 更新者:Vardakis Panagiotis、University of Crete

The Effect of Pain Treatment on Brain-Derived Exosomal Load, Cognitive Function, and Sleep Disturbances in Patients With Fibromyalgia: A Pilot, Prospective, Controlled, Observational Trial

The goal of this observational study is to learn about the effects of electroacupuncture on exosome load and clinical outcomes in patients with fibromyalgia, a chronic condition characterized by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction.

The main questions it aims to answer are:

  1. Does acupuncture alter the load of circulating exosomes in patients with fibromyalgia?
  2. Is a change in exosome load associated with improvements in pain, cognitive function, and sleep quality?
  3. Can exosome load serve as a potential biomarker of brain-related changes in conditions involving chronic pain?

Participants with fibromyalgia receiving electroacupuncture as part of their routine clinical care will provide blood samples before and after treatment for exosome analysis. Participants will also undergo assessments of mechanical pain threshold, pain intensity, overall symptom burden, cognitive function (using objective neuropsychological tests and self-report questionnaires), and sleep quality. Healthy volunteers will be included as a comparison group.

調査の概要

状態

まだ募集していません

詳細な説明

Chronic pain has emerged as a major public health challenge, affecting millions of individuals worldwide and imposing a substantial socioeconomic burden. Beyond physical suffering, chronic pain is increasingly recognized as a condition associated with cognitive impairment, including deficits in memory, attention, executive function, and information processing.

According to the neural resource theory, persistent pain continuously consumes cognitive resources, thereby reducing the brain's ability to perform higher cognitive tasks. However, several additional mechanisms have been proposed, including neuroplastic alterations, neuroinflammation mediated by microglial activation, psychosocial factors, and disturbances of the gut-brain axis.

Recent advances in extracellular vesicle biology have highlighted the importance of exosomes as mediators of intercellular communication. Brain-derived exosomes are capable of crossing the blood-brain barrier and carry proteins, lipids, messenger RNAs, microRNAs, and other molecular cargo reflecting ongoing pathological processes within the central nervous system. Emerging evidence suggests altered exosomal microRNA profiles in fibromyalgia patients, while other studies have demonstrated associations between exosome-related biomarkers and neurodegenerative processes, cognitive decline, and sleep disorders. Nevertheless, review of the literature suggests that no study has comprehensively investigated the relationship between exosomal alterations, cognitive dysfunction, sleep disturbances, and response to electroacupuncture in fibromyalgia.

Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction. Cognitive symptoms, often described as "fibro fog," significantly impair daily functioning and quality of life. Despite increasing recognition of these manifestations, the biological mechanisms linking chronic pain to cognitive impairment remain poorly understood. Fibromyalgia represents an ideal clinical model for investigating these interactions because it combines chronic widespread pain with pronounced cognitive dysfunction and sleep disturbances. Previous studies have demonstrated alterations in functional brain networks, inflammatory pathways, and neuroendocrine regulation in patients with fibromyalgia.

The overall objective of this study is to investigate whether brain-derived exosomes can serve as biomarkers of pain-related cognitive dysfunction and sleep disturbances in patients with fibromyalgia and whether their profile is modified following pain treatment.

The specific objectives are:

  1. To compare brain-derived exosomal load between patients with fibromyalgia and healthy controls.
  2. To evaluate the effects of electroacupuncture on exosomal load and composition.
  3. To assess the relationship between exosomal load and clinical outcomes, including pain severity, symptom burden, cognitive performance, and sleep quality.
  4. To explore whether changes in exosomal load correlate with treatment-induced clinical improvement.

研究の種類

観察的

入学 (推定)

30

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Crete
      • Heraklion、Crete、ギリシャ、71110
        • Medical School, University of Crete

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Participants that are included in the Fibromyalgia Cohort, are patients with widespread musculoskeletal pain, who are referred to Chronic Pain Clinic of University hospital of Heraklion from Rheumatologists, after excluding other rheumatologist diseases and confirming the diagnosis of Fibromyalgia. They will be enrolled in the study if only they meet inclusion criteria and they do not meet exclusion criteria Participants in the Healthy Cohort, are healthy volunteers, that meet inclusion criteria of the study.

説明

Inclusion Criteria:

Inclusion Criteria for the Healthy Cohort

Participants will be eligible for inclusion in the Healthy Cohort group if they meet all of the following criteria:

  1. Age between 18 and 70 years.
  2. Absence of any chronic pain condition or other medical disorder known to affect systemic inflammatory burden during the study period.
  3. Absence of cognitive impairment, as assessed by the Montreal Cognitive Assessment (MoCA) and the Trail Making Test (TMT) Parts A and B. The criterion for the absence of cognitive impairment, as assessed by the Montreal Cognitive Assessment (MoCA), is a score of 26 or higher (≥26), as recommended in the literature.
  4. Absence of poor sleep quality, defined according to the Pittsburgh Sleep Quality Index (PSQI).
  5. No history of depression or other neuropsychiatric disorders. If healthy volunteers are found to have depression or any other neuropsychiatric disorder, they will be immediately referred for psychiatric and psychological assessment.
  6. No use of antidepressant medications or sleep-promoting agents, including herbal or over-the-counter sleep aids.

Inclusion Criteria for the Fibromyalgia Cohort

Participants will be eligible for inclusion in the fibromyalgia group if they meet all of the follow-ing criteria:

  1. Diagnosis of fibromyalgia established by a rheumatologist according to the American College of Rheumatology (ACR) 2010 classification criteria.
  2. Age between 18 and 70 years.
  3. Moderate-to-severe pain intensity, defined as a Visual Analogue Scale (VAS) score ≥ 4/10.
  4. Presence of cognitive difficulties documented through the Montreal Cognitive Assess-ment (MoCA) and the Trail Making Test (TMT) Parts A and B. The criterion for the presence of cognitive impairment, as assessed by the Montreal Cognitive Assessment (MoCA), is a score below 26.
  5. Poor sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≥ 5.

Exclusion Criteria:

Exclusion Criteria for the Fibromyalgia Group

Participants meeting any of the following criteria will be excluded from the study:

  1. Coexisting neurological disorders associated with cognitive impairment, including dementia.
  2. Coexisting psychiatric disorders known to affect cognitive function, including major depressive disorder, bipolar disorder, or schizophrenia. Major depression will be defined as a Patient Health Questionnaire-9 (PHQ-9) score ≥ 20.
  3. Presence of medical conditions associated with altered inflammatory burden, including rheumatologic diseases.
  4. Use of sleep medications that cannot be safely discontinued prior to study participation.
  5. Antidepressant treatment that cannot either be discontinued or maintained at a stable dosage for at least three months before treatment initiation and throughout the entire study period.

5. Severe cognitive impairment resulting in an inability to understand the Participant Information Sheet and provide informed consent, as assessed by the Montreal Cognitive Assessment (MoCA). Patients with a score below 18/30 will be excluded from the study and referred to the appropriate healthcare professional for further assessment and management.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_CONTROL
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Fibromyalgia cohort

Patients diagnosed with Fibromyalgia

**Electroacupuncture Intervention**

Participants in this group will receive electroacupuncture treatment for 24 weeks. During the first 6 weeks, treatment sessions will be administered twice weekly. Thereafter, participants will receive maintenance treatments every two weeks until completion of the 24-week intervention period.

A standardized electroacupuncture protocol will be applied using the following acupuncture points:

  • GV20 (Baihui)
  • EX-HN3 (Yintang)
  • BL10 (Tianzhu)
  • GB21 (Jianjing)
  • BL60 (Kunlun)
  • ST36 (Zusanli)
  • LV3 (Taichong)
  • SP6 (Sanyinjiao)
  • LI4 (Hegu)
  • LI11 (Quchi)
  • KI3 (Taixi)
  • CV6 (Qihai)
  • CV12 (Zhongwan)
  • HT7 (Shenmen) Additional individualized points will be used if required.

Sterile, single-use disposable needles will be inserted at the specified acupoints. Electrical stimulation will be applied according to the study protocol.

Healthy cohort

Healthy volunteers, age, sex and education level matched to Fibromyalgia cohort

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Brain-derived exosomes - Changes in exosomal load
時間枠:In the Fibromyalgia Cohort this outcome will be assessed before treatment, at 6 weeks, and at 6 months after treatment initiation. In the Healthy Cohort this outcome will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

Changes in exosomal cargo, exosomal protein expression and molecular signatures relevant to neuroinflammation, neuronal dysfunction, and neurodegeneration will be analyzed by comprehensive proteomic profiling of exosomes (label-free, non-targeted proteomics). This outcome will be assessed in both Cohorts of the study.

In the Fibromyalgia Cohort this outcome will be assessed before treatment, at 6 weeks, and at 6 months after treatment initiation. In the Healthy Cohort this outcome will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective Cognitive Assessment - Greek version of the Trail Making Test (TMT) Part A
時間枠:For participants belonging to the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

Objective changes in cognitive function from treatment will be assessed using the Greek version of the Trail Making Test (TMT) Part A. Raw scores will be converted to age-, sex-, and education-adjusted z-scores using Greek normative data to facilitate comparisons between groups. This outcome will be assessed in both groups.

For participants belonging to the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.
Objective Cognitive Assessment - Greek version of the Trail Making Test (TMT) Part B
時間枠:For participants in the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.

Objective changes in cognitive function from treatment will be assessed using the Greek version of the Trail Making Test (TMT) Part B. Raw scores will be converted to age-, sex-, and education-adjusted z-scores using Greek normative data to facilitate comparisons between groups. This outcome will be assessed in both groups.

For participants in the Fibromyalgia Cohort, scores will be assessed Before treatment (baseline), at 6 weeks, and at 6 months. In the Healthy Cohort, scores will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment.
Pain Assessment - BPI Short Form questionnaire - Change of Pain Interference score
時間枠:Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

Pain's impact on participants' daily functioning will be assessed using the Brief Pain Inventory (BPI) Short form questionnaire. The Pain Interference score will be calculated by adding the scores from Items 9A-9G and divided by 7. This outcome will be assessed only in Fibromyalgia Cohort.

Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.
Pain Assessment - BPI Short Form questionnaire - Change of Pain severity score
時間枠:Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

Pain intensity will be assessed using the Brief Pain Inventory (BPI) Short Form questionnaire. The Pain severity score will be calculated by adding the scores from Items 3-6 and divided by 4. This outcome will be assessed only in Fibromyalgia Cohort.

Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.
Pain Assessment - BPI Short Form questionnaire - Change of percentage relief from treatment
時間枠:Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

Pain relief from treatment will be assessed using the Brief Pain Inventory (BPI) Short Form questionnaire. The Pain relief from treatment will be assessed by Items 8 of questionnaire. This outcome will be assessed only in Fibromyalgia Cohort.

Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.
Pain Assessment - Algometer - Change of Mechanical threshold of Pain
時間枠:Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.

Mechanical threshold of participants' pain in Fibromyalgia Cohort will be assessed using the Algometer. By the algometer pressure will be applied to two-four painful points and the patients will indicate by pressing a button the pressure that provokes pain. This outcome will be assessed only in Fibromyalgia Cohort.

Before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation. This is applicable only to participants in the Fibromyalgia Cohort, as participants in Healthy Cohort do not experience pain.
Objective Cognitive Assessment - Greek version of Montreal Cognitive Assessment Test (MoCA)
時間枠:For participants in the Fibromyalgia Cohort, scores will be assessed before treatment (baseline), at 6 weeks, and at 6 months. Scores in the Healthy Cohort will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment in study.

Objective changes in cognitive function from treatment will be assessed using the Greek Version of Montreal Cognitive Assessment Test (MoCA) . Scores will result from summing the scores from the individual tests of MOCA as indicated from the authors. This outcome will be assessed in both groups.

For participants in the Fibromyalgia Cohort, scores will be assessed before treatment (baseline), at 6 weeks, and at 6 months. Scores in the Healthy Cohort will be assessed before enrollment, at 6 weeks, and at 6 months after enrollment in study.
Sleep Disturbances - Pittsburgh Sleep Quality Index (PSQI)
時間枠:The scores will be assessed in both cohorts before enrollment in the study, at 6 weeks and 6 months after enrollment.

Sleep quality changes will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated instrument for the evaluation of subjective sleep quality and sleep-related disturbances. It groups 19 self-rated questions into 7 component scores, each graded on a scale of 0 to 3. The global score ranges from 0 to 21 and a global score greater than 5 indicates poor sleep quality.

The scores will be assessed in both cohorts before enrollment in the study, at 6 weeks and 6 months after enrollment.
Subjective Cognitive Assessment - Revised Fibromyalgia Impact Questionnaire (FIQ-R) - Changes in cognitive function
時間枠:Scores will be assessed only in the Fibromyalgia Cohort before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation, because participants in Healthy Cohort do not experience pain.

Changes in cognitive function will be assessed using the cognitive subscale of the Revised Fibromyalgia Impact Questionnaire (FIQ-R), which evaluates patients' self-perceived cognitive difficulties. In this sub scale the patient is asked to rate the severity of specific cognitive issues over the past 7 days on a 0-10 numeric scale. This outcome will be assessed only in Fibromyalgia Cohort.

Scores will be assessed only in the Fibromyalgia Cohort before treatment (baseline), at the end of the initial intervention phase (6 weeks), and at 6 months after treatment initiation, because participants in Healthy Cohort do not experience pain.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年11月1日

研究の完了 (推定)

2028年11月1日

試験登録日

最初に提出

2026年11月16日

QC基準を満たした最初の提出物

2026年11月16日

最初の投稿 (実際)

2026年11月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する